Skip to main
VKTX

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics (VKTX) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 36%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Viking Therapeutics Inc. is poised for significant growth due to its strategic clinical program pipeline and upcoming product introductions, including VK2735 and an amylin agonist IND, which are expected to enhance investor sentiment. The company’s advanced standing among independent late-stage metabolic players positions it favorably as the market for such assets becomes increasingly scarce. Additionally, Viking's maturity and data strength are likely to attract favorable partnership opportunities and financing terms, contributing to a positive long-term outlook.

Bears say

Viking Therapeutics Inc faces significant risks inherent to the biopharmaceutical industry, particularly concerning unexpected outcomes from clinical trials and regulatory uncertainties that could impede product development. Furthermore, the company operates in an increasingly complex and price-sensitive commercial landscape, which may hinder the profitability of its product candidates. The heightened scrutiny on licensing agreements, especially in U.S.-China contexts, adds another layer of challenge that may adversely affect Viking's strategic partnerships and growth potential.

Viking Therapeutics (VKTX) has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 36% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viking Therapeutics (VKTX) Forecast

Analysts have given Viking Therapeutics (VKTX) a Buy based on their latest research and market trends.

According to 14 analysts, Viking Therapeutics (VKTX) has a Buy consensus rating as of Jan 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $87.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $87.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viking Therapeutics (VKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.